Toronto, Ontario–(Newsfile Corp. – September 10, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”) announced today that an annual general and special meeting (the “Meeting”) of the common shareholders will be held in person at 10:00 a.m. (Toronto time) on Wednesday October 9, 2024, at 1430 Hurontario Street, Mississauga, Ontario, L5G 3H4.
Please note that shareholders will not be entitled to vote at, or otherwise participate in, the Meeting by way of teleconference or other electronic means, and so we encourage shareholders to vote in advance of the Meeting in accordance with the instructions provided in the materials for the Meeting, including the Management Information Circular, which is available on SEDAR+ as well as the Company’s website.
About Braxia Scientific Corp.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga and Ottawa.
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
FOR FURTHER INFORMATION PLEASE CONTACT:
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.